公开(公告)号：US11718668B2

公开(公告)日：2023-08-08

申请号：US17739274

申请日：2022-05-09

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K16/40 ,  C12Q1/6886 ,  C12Y113/11052 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/00 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US20220259312A1

公开(公告)日：2022-08-18

申请号：US17739278

申请日：2022-05-09

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US11753468B2

公开(公告)日：2023-09-12

申请号：US17952919

申请日：2022-09-26

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K16/40 ,  C12Q1/6886 ,  C12Y113/11052 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/00 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US11643462B2

公开(公告)日：2023-05-09

申请号：US17354653

申请日：2021-06-22

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K16/40 ,  C12Q1/6886 ,  C12Y113/11052 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/00 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US20230026716A1

公开(公告)日：2023-01-26

申请号：US17952919

申请日：2022-09-26

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US20210107978A1

公开(公告)日：2021-04-15

申请号：US17131339

申请日：2020-12-22

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US20220275086A1

公开(公告)日：2022-09-01

申请号：US17739274

申请日：2022-05-09

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US11339219B2

公开(公告)日：2022-05-24

申请号：US17131328

申请日：2020-12-22

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US11325974B2

公开(公告)日：2022-05-10

申请号：US17131326

申请日：2020-12-22

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US20160193239A1

公开(公告)日：2016-07-07

申请号：US14916235

申请日：2014-09-05

Applicant: The Johns Hopkins University

Inventor： Stephen B. Baylin ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: A61K31/706 ,  A61K45/06 ,  C12Q1/68 ,  A61K39/395

CPC classification number: A61K31/706 ,  A61K31/167 ,  A61K38/15 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2827 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/154 ,  A61K2300/00

Abstract: Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.

Abstract translation: 公开了将表观遗传调节剂与免疫调节剂结合的癌症疗法，其被显着地鉴定为提供改善的治疗方案，超过单一药物治疗。 在具体实施方案中，本发明提供通过施用示例性免疫调节剂抗PD-1抗体或抗-PD-L1抗体来改善患者中NSCLC的治疗，所述抗PD-1抗体或抗-PD-L1抗体观察到与示例性表观遗传调节剂组合显示增强的活性 5-脱氧氮杂胞苷。 此外，还公开了响应性肿瘤细胞的表达标志物。